London, UK, 2 Jan 2007. Plasticell Ltd, the UK biotechnology company developing drugs to regenerate tissues of the body, has relocated its offices and laboratories to the newly opened Imperial BioIncubator, a facility managed by Imperial Innovations and sited at Imperial College London’s South Kensington campus. Plasticell is the first external company to be admitted to the BioIncubator and joins a number of Imperial College spin-outs.
Commenting on the move Dr Yen Choo, Plasticell’s Chief Executive, said: “I am extremely grateful to Medical Research Council Technology, which previously incubated Plasticell as it progressed through the crucial seed stage. I now look forward to the company’s next phase of development at Imperial College, and the new possibilities brought about by our relocation: in particular the opportunity to interact closely with both scientists and engineers, and to benefit from the strong entrepreneurial culture of the College, which was recently ranked fourth in the world for biomedical research.”
Susan Searle, Chief Executive, Imperial Innovations said: “I am delighted to welcome Plasticell to the BioIncubator and I encourage the company to take full advantage of the fantastic academic and entrepreneurial environment at Imperial College London. We look forward to welcoming more external companies to the facility.”
Plasticell is a privately held biotechnology company using innovative, high throughput stem cell technologies and novel drug discovery platforms to dissect the mechanisms leading to differentiation of stem cells, the master cells responsible for tissue development and repair. Plasticell’s research focus is to discover regenerative small molecule drugs. The company also forms industry alliances by partnering its Combinatorial Cell Culture™ technology for high throughput stem cell differentiation, to derive cell lines and reagents for research and therapy applications. For more information please visit the company’s website: www.plasticell.co.uk
About Imperial Innovations
Imperial Innovations is one of the UK’s leading technology transfer and commercialisation companies. The company was founded in 1986 and was admitted to the AIM Market of London Stock Exchange plc in July 2006, raising £26 million. The company’s integrated approach encompasses the identification of ideas, protection of intellectual property, development and licensing of technology and formation, incubation and investment in technology businesses. A wide range of technologies are commercialised within the areas of healthcare, energy, environment and emerging technology trends. For more information please visit the company’s website: www.imperialinnovations.co.uk